ChartRow logo
Data provided bySource: Twelve Data
CORT
$70.07+1.23%
as of close, Nov 17, 2026
☾ AH $70.07 +1.23%
PeersHALOALNYTWSTKRYSHLPCVX
Share this page

CORT SEC filings (2026)

CIK 1088856 · Pharmaceutical Preparations (SIC 2834) · incorporated in DE · fiscal year ends in December

2,045 filings on EDGAR since 2001 · 24 annual, 70 quarterly, 244 current · financial statements · earnings

Latest 10-K
Feb 24, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Nov 3, 2026
quarter to Sep 30, 2026
Latest 8-K
Nov 3, 2026
Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
Last earnings release
Nov 3, 2026
$1.01 vs $0.68 · ▼ 3.3%
Filings on file
2,045
since 2001, 1,342 insider forms

What happened, last 12 months#

Every earnings release with its print, every report with its quarter, the other 8-Ks by the headline of the press release they furnish or by their items, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.

November 2026

October 2026

September 2026

August 2026

July 2026

June 2026

May 2026

April 2026

March 2026

February 2026

January 2026

December 2025

Insider transactions#

What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.

Over the last 13 months insiders sold $91.3M in 49 sales and bought $3.3M in 1 purchase; 144 other transactions (awards, exercises, tax withholding, gifts and plan purchases).

DateInsider
Nov 13, 2026Form 4WILSON JAMES NDirectorSold · $727K · 10,000 sh · 10b5-1
Nov 10, 2026Form 4Swisher Daniel N JRDirectorSold · $111K · 1,500 sh · 10b5-1
Nov 3, 2026Form 4Maduck SeanSee RemarksSold · $1.1M · 13,159 sh · 10b5-1
Nov 2, 2026Form 4Maduck SeanSee RemarksSold · $964K · 11,841 sh · 10b5-1
Nov 2, 2026Form 4Vieira Roberto WandenkolkPresident, OncologySold · $674K · 8,333 sh · 10b5-1
Oct 15, 2026Form 4WILSON JAMES NDirectorSold · $1.1M · 10,000 sh · 10b5-1
Oct 2, 2026Form 4Maduck SeanSee RemarksSold · $2.9M · 24,587 sh · 10b5-1
Oct 2, 2026Form 4Lyon Joseph DouglasSee RemarksSold · $1.1M · 9,190 sh · 10b5-1
Oct 2, 2026Form 4Vieira Roberto WandenkolkPresident, OncologySold · $967K · 8,333 sh · 10b5-1
Oct 1, 2026Form 4Lyon Joseph DouglasSee RemarksSold · $93K · 810 sh · 10b5-1
Oct 1, 2026Form 4Maduck SeanSee RemarksSold · $48K · 413 sh · 10b5-1
Sep 16, 2026Form 4Vieira Roberto WandenkolkPresident, OncologySold · $30K · 296 sh · 10b5-1
Sep 15, 2026Form 4WILSON JAMES NDirectorSold · $1.1M · 10,000 sh · 10b5-1
Sep 14, 2026Form 4Lyon Joseph DouglasSee RemarksSold · $1.1M · 10,000 sh · 10b5-1
Sep 2, 2026Form 4Vieira Roberto WandenkolkPresident, OncologySold · $6.5M · 58,333 sh · 10b5-1
Sep 1, 2026Form 4Maduck SeanSee RemarksSold · $2.9M · 25,000 sh · 10b5-1
Aug 26, 2026Form 4Park KimberlyDirectorSold · $3.3M · 26,685 sh
Aug 25, 2026Form 4Maduck SeanSee RemarksSold · $3.9M · 30,955 sh · 10b5-1
Aug 18, 2026Form 4MAHONEY DAVID LDirectorSold · $12.3M · 103,606 sh · 10b5-1
Aug 17, 2026Form 4Robb Gary CharlesChief Business OfficerSold · $1.2M · 10,000 sh
Aug 14, 2026Form 4WILSON JAMES NDirectorSold · $1.1M · 10,000 sh · 10b5-1
Aug 14, 2026Form 4Maduck SeanSee RemarksSold · $419K · 3,664 sh · 10b5-1
Aug 10, 2026Form 4Guyer WilliamChief Development OfficerSold · $1.8M · 16,300 sh · 10b5-1
Aug 10, 2026Form 4Maduck SeanSee RemarksSold · $118K · 1,031 sh · 10b5-1
Aug 4, 2026Form 4Guyer WilliamChief Development OfficerSold · $419K · 3,700 sh · 10b5-1
Aug 3, 2026Form 4Maduck SeanSee RemarksSold · $2.3M · 20,305 sh · 10b5-1
Aug 3, 2026Form 4Lyon Joseph DouglasSee RemarksSold · $176K · 1,540 sh
Jul 30, 2026Form 4Mokari AtabakChief Financial OfficerSold · $9.2M · 80,000 sh · 10b5-1
Jul 15, 2026Form 4Mokari AtabakChief Financial OfficerSold · $3.5M · 40,000 sh · 10b5-1
Jul 15, 2026Form 4WILSON JAMES NDirectorSold · $883K · 10,000 sh · 10b5-1
Jul 7, 2026Form 4Guyer WilliamChief Development OfficerSold · $1.9M · 20,000 sh · 10b5-1
Jul 1, 2026Form 4Maduck SeanSee RemarksSold · $2.2M · 25,000 sh · 10b5-1
Jun 17, 2026Form 4MAHONEY DAVID LDirectorSold · $1.7M · 20,000 sh
Jun 16, 2026Form 4WILSON JAMES NDirectorSold · $832K · 10,000 sh · 10b5-1
Jun 15, 2026Form 4Mokari AtabakChief Financial OfficerSold · $3.2M · 40,000 sh · 10b5-1
Jun 2, 2026Form 4Guyer WilliamChief Development OfficerSold · $1.4M · 20,000 sh · 10b5-1
Jun 1, 2026Form 4Mokari AtabakChief Financial OfficerSold · $2.8M · 40,000 sh · 10b5-1
Jun 1, 2026Form 4Maduck SeanSee RemarksSold · $1.8M · 25,000 sh · 10b5-1
Jun 1, 2026Form 4BELANOFF JOSEPH KChief Executive Officer · DirectorSold · $895K · 12,837 sh · 10b5-1
May 27, 2026Form 4Maduck SeanSee RemarksSold · $4.9M · 75,000 sh · 10b5-1
May 27, 2026Form 4Lyon Joseph DouglasSee RemarksSold · $325K · 5,000 sh
May 5, 2026Form 4Guyer WilliamChief Development OfficerSold · $1.0M · 20,000 sh · 10b5-1
May 1, 2026Form 4BELANOFF JOSEPH KChief Executive Officer · DirectorSold · $2.0M · 40,000 sh · 10b5-1
Apr 7, 2026Form 4Guyer WilliamChief Development OfficerSold · $819K · 20,000 sh · 10b5-1
Mar 25, 2026Form 4BELANOFF JOSEPH KChief Executive Officer · DirectorSold · $1.3M · 26,198 sh · 10b5-1
Mar 20, 2026Form 4Guyer WilliamChief Development OfficerSold · $424K · 11,767 sh · 10b5-1
Mar 17, 2026Form 4BAKER G LEONARD JRDirectorBought · $3.3M · 100,000 sh
Mar 4, 2026Form 4Guyer WilliamChief Development OfficerSold · $296K · 8,233 sh · 10b5-1
Feb 3, 2026Form 4Guyer WilliamChief Development OfficerSold · $817K · 20,000 sh · 10b5-1
Jan 6, 2026Form 4Guyer WilliamChief Development OfficerSold · $704K · 20,000 sh · 10b5-1
Awards, exercises, withholding and plan purchases · 144 transactions
DateInsider
Nov 10, 2026Form 4Swisher Daniel N JRDirectorExercise or conversion · $20K · 1,500 sh · 10b5-1
Nov 10, 2026Form 4Swisher Daniel N JRDirectorExercise or conversion · Stock Option (right to buy) · $0 · 1,500 sh · 10b5-1
Nov 3, 2026Form 4Maduck SeanSee RemarksExercise or conversion · $109K · 13,159 sh · 10b5-1
Nov 3, 2026Form 4Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 13,159 sh · 10b5-1
Nov 2, 2026Form 4Vieira Roberto WandenkolkPresident, OncologyExercise or conversion · $180K · 8,333 sh · 10b5-1
Nov 2, 2026Form 4Maduck SeanSee RemarksExercise or conversion · $98K · 11,841 sh · 10b5-1
Nov 2, 2026Form 4Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 11,841 sh · 10b5-1
Nov 2, 2026Form 4Vieira Roberto WandenkolkPresident, OncologyExercise or conversion · Stock option (right to buy) · $0 · 8,333 sh · 10b5-1
Oct 2, 2026Form 4Maduck SeanSee RemarksExercise or conversion · $203K · 24,587 sh · 10b5-1
Oct 2, 2026Form 4Vieira Roberto WandenkolkPresident, OncologyExercise or conversion · $180K · 8,333 sh · 10b5-1
Oct 2, 2026Form 4Lyon Joseph DouglasSee RemarksExercise or conversion · $158K · 9,190 sh · 10b5-1
Oct 2, 2026Form 4Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 24,587 sh · 10b5-1
Oct 2, 2026Form 4Lyon Joseph DouglasSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 9,190 sh · 10b5-1
Oct 2, 2026Form 4Vieira Roberto WandenkolkPresident, OncologyExercise or conversion · Stock option (right to buy) · $0 · 8,333 sh · 10b5-1
Oct 1, 2026Form 4Lyon Joseph DouglasSee RemarksExercise or conversion · $11K · 810 sh · 10b5-1
Oct 1, 2026Form 4Maduck SeanSee RemarksExercise or conversion · $3,416 · 413 sh · 10b5-1
Oct 1, 2026Form 4Gunn Justin FrederickSee RemarksAward · Stock Option (right to buy) · $0 · 100,000 sh
Oct 1, 2026Form 4Lyon Joseph DouglasSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 810 sh · 10b5-1
Oct 1, 2026Form 4Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 413 sh · 10b5-1
Sep 24, 2026Form 4Robb Gary CharlesChief Business OfficerGift · $0 · 27,100 sh
Sep 17, 2026Form 4Robb Gary CharlesChief Business OfficerExercise or conversion · $145K · 17,493 sh
Sep 17, 2026Form 4Robb Gary CharlesChief Business OfficerExercise or conversion · Stock option (right to buy) · $0 · 17,493 sh
Sep 14, 2026Form 4Lyon Joseph DouglasSee RemarksExercise or conversion · $130K · 10,000 sh · 10b5-1
Sep 14, 2026Form 4Lyon Joseph DouglasSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 10,000 sh · 10b5-1
Sep 2, 2026Form 4Vieira Roberto WandenkolkPresident, OncologyExercise or conversion · $1.3M · 58,333 sh · 10b5-1
Sep 2, 2026Form 4Maduck SeanSee RemarksTax withholding · $13K · 117 sh · 10b5-1
Sep 2, 2026Form 4Vieira Roberto WandenkolkPresident, OncologyTax withholding · $12K · 102 sh · 10b5-1
Sep 2, 2026Form 4Mokari AtabakChief Financial OfficerTax withholding · $12K · 102 sh
Sep 2, 2026Form 4Robb Gary CharlesChief Business OfficerTax withholding · $10K · 91 sh
Sep 2, 2026Form 4Lyon Joseph DouglasSee RemarksTax withholding · $8,163 · 72 sh
Sep 2, 2026Form 4Vieira Roberto WandenkolkPresident, OncologyExercise or conversion · Stock option (right to buy) · $0 · 58,333 sh · 10b5-1
Sep 1, 2026Form 4Maduck SeanSee RemarksExercise or conversion · $207K · 25,000 sh · 10b5-1
Sep 1, 2026Form 4Robb Gary CharlesChief Business OfficerAward · $19K · 328 sh
Sep 1, 2026Form 4Guyer WilliamChief Development OfficerAward · $19K · 328 sh
Sep 1, 2026Form 4Maduck SeanSee RemarksAward · $17K · 300 sh · 10b5-1
Sep 1, 2026Form 4Vieira Roberto WandenkolkPresident, OncologyAward · $16K · 276 sh · 10b5-1
Sep 1, 2026Form 4Mokari AtabakChief Financial OfficerAward · $16K · 276 sh
Sep 1, 2026Form 4Lyon Joseph DouglasSee RemarksAward · $15K · 260 sh
Sep 1, 2026Form 4Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 25,000 sh · 10b5-1
Aug 26, 2026Form 4Park KimberlyDirectorTax withholding · $405K · 3,315 sh
Aug 26, 2026Form 4Park KimberlyDirectorExercise or conversion · $405K · 30,000 sh
Aug 26, 2026Form 4Park KimberlyDirectorExercise or conversion · Stock Option (right to buy) · $0 · 30,000 sh
Aug 25, 2026Form 4Maduck SeanSee RemarksExercise or conversion · $351K · 30,955 sh · 10b5-1
Aug 25, 2026Form 4Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 30,955 sh · 10b5-1
Aug 17, 2026Form 4Robb Gary CharlesChief Business OfficerGift · $0 · 125 sh
Aug 14, 2026Form 4Maduck SeanSee RemarksExercise or conversion · $30K · 3,664 sh · 10b5-1
Aug 14, 2026Form 4Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 3,664 sh · 10b5-1
Aug 12, 2026Form 4Robb Gary CharlesChief Business OfficerGift · $0 · 17,530 sh
Aug 10, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · $353K · 16,300 sh · 10b5-1
Aug 10, 2026Form 4Maduck SeanSee RemarksExercise or conversion · $8,526 · 1,031 sh · 10b5-1
Aug 10, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 16,300 sh · 10b5-1
Aug 10, 2026Form 4Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 1,031 sh · 10b5-1
Aug 4, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · $80K · 3,700 sh · 10b5-1
Aug 4, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 3,700 sh · 10b5-1
Aug 3, 2026Form 4Maduck SeanSee RemarksExercise or conversion · $168K · 20,305 sh · 10b5-1
Aug 3, 2026Form 4Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 20,305 sh · 10b5-1
Jul 30, 2026Form 4Mokari AtabakChief Financial OfficerExercise or conversion · $1.8M · 80,000 sh · 10b5-1
Jul 30, 2026Form 4Mokari AtabakChief Financial OfficerExercise or conversion · Stock option (right to buy) · $0 · 80,000 sh · 10b5-1
Jul 15, 2026Form 4Mokari AtabakChief Financial OfficerExercise or conversion · $862K · 40,000 sh · 10b5-1
Jul 15, 2026Form 4Mokari AtabakChief Financial OfficerExercise or conversion · Stock option (right to buy) · $0 · 40,000 sh · 10b5-1
Jul 7, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · $433K · 20,000 sh · 10b5-1
Jul 7, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 20,000 sh · 10b5-1
Jul 1, 2026Form 4Maduck SeanSee RemarksExercise or conversion · $207K · 25,000 sh · 10b5-1
Jul 1, 2026Form 4Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 25,000 sh · 10b5-1
Jun 15, 2026Form 4Mokari AtabakChief Financial OfficerExercise or conversion · $770K · 40,000 sh · 10b5-1
Jun 15, 2026Form 4Mokari AtabakChief Financial OfficerExercise or conversion · Stock option (right to buy) · $0 · 40,000 sh · 10b5-1
Jun 2, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · $433K · 20,000 sh · 10b5-1
Jun 2, 2026Form 4Maduck SeanSee RemarksTax withholding · $32K · 452 sh · 10b5-1
Jun 2, 2026Form 4Mokari AtabakChief Financial OfficerTax withholding · $28K · 395 sh · 10b5-1
Jun 2, 2026Form 4Robb Gary CharlesChief Business OfficerTax withholding · $25K · 358 sh
Jun 2, 2026Form 4Lyon Joseph DouglasSee RemarksTax withholding · $19K · 269 sh
Jun 2, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 20,000 sh · 10b5-1
Jun 1, 2026Form 4Mokari AtabakChief Financial OfficerExercise or conversion · $770K · 40,000 sh · 10b5-1
Jun 1, 2026Form 4Maduck SeanSee RemarksExercise or conversion · $207K · 25,000 sh · 10b5-1
Jun 1, 2026Form 4Guyer WilliamChief Development OfficerAward · $62K · 1,754 sh
Jun 1, 2026Form 4Robb Gary CharlesChief Business OfficerAward · $55K · 1,552 sh
Jun 1, 2026Form 4Mokari AtabakChief Financial OfficerAward · $45K · 1,268 sh · 10b5-1
Jun 1, 2026Form 4Maduck SeanSee RemarksAward · $43K · 1,230 sh · 10b5-1
Jun 1, 2026Form 4Lyon Joseph DouglasSee RemarksAward · $38K · 1,074 sh
Jun 1, 2026Form 4Mokari AtabakChief Financial OfficerExercise or conversion · Stock option (right to buy) · $0 · 40,000 sh · 10b5-1
Jun 1, 2026Form 4Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 25,000 sh · 10b5-1
May 29, 2026Form 4BELANOFF JOSEPH KChief Executive Officer · DirectorGift · $0 · 600,000 sh · 10b5-1
May 27, 2026Form 4Maduck SeanSee RemarksExercise or conversion · $620K · 75,000 sh · 10b5-1
May 27, 2026Form 4WILSON JAMES NDirectorGift · $0 · 910,078 sh
May 27, 2026Form 4Maduck SeanSee RemarksExercise or conversion · Stock option (right to buy) · $0 · 75,000 sh · 10b5-1
May 27, 2026Form 4Robb Gary CharlesChief Business OfficerGift · $0 · 600 sh
May 21, 2026Form 4Park KimberlyDirectorAward · Stock Option (right to buy) · $0 · 12,500 sh
May 21, 2026Form 4MAHONEY DAVID LDirectorAward · Stock Option (right to buy) · $0 · 12,500 sh
May 21, 2026Form 4Murray Joshua M.DirectorAward · Stock Option (right to buy) · $0 · 12,500 sh
May 21, 2026Form 4Swisher Daniel N JRDirectorAward · Stock Option (right to buy) · $0 · 12,500 sh
May 21, 2026Form 4WILSON JAMES NDirectorAward · Stock Option (right to buy) · $0 · 12,500 sh
May 21, 2026Form 4Alton Gregg HDirectorAward · Stock Option (right to buy) · $0 · 12,500 sh
May 21, 2026Form 4BAKER G LEONARD JRDirectorAward · Stock Option (Right To Buy) · $0 · 12,500 sh
May 13, 2026Form 4Robb Gary CharlesChief Business OfficerGift · $0 · 7,300 sh
May 5, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · $433K · 20,000 sh · 10b5-1
May 5, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 20,000 sh · 10b5-1
Apr 22, 2026Form 4WILSON JAMES NDirectorGift · $0 · 2,000 sh
Apr 7, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · $433K · 20,000 sh · 10b5-1
Apr 7, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 20,000 sh · 10b5-1
Apr 6, 2026Form 4WILSON JAMES NDirectorGift · $0 · 5,000 sh
Mar 20, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · $255K · 11,767 sh · 10b5-1
Mar 20, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 11,767 sh · 10b5-1
Mar 20, 2026Form 4WILSON JAMES NDirectorGift · $0 · 4,000 sh
Mar 13, 2026Form 4MAHONEY DAVID LDirectorTax withholding · $176K · 5,469 sh
Mar 13, 2026Form 4MAHONEY DAVID LDirectorExercise or conversion · $176K · 30,000 sh
Mar 13, 2026Form 4MAHONEY DAVID LDirectorExercise or conversion · Stock Option (right to buy) · $0 · 30,000 sh
Mar 13, 2026Form 4WILSON JAMES NDirectorGift · $0 · 28,000 sh
Mar 13, 2026Form 4MAHONEY DAVID LDirectorGift · $0 · 24,531 sh
Mar 13, 2026Form 4MAHONEY DAVID LDirectorOther · $0 · 24,531 sh
Mar 4, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · $178K · 8,233 sh · 10b5-1
Mar 4, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · Stock Option (right to buy) · $0 · 8,233 sh · 10b5-1
Mar 3, 2026Form 4Robb Gary CharlesChief Business OfficerTax withholding · $4,352 · 121 sh
Mar 3, 2026Form 4Maduck SeanSee RemarksTax withholding · $3,957 · 110 sh
Mar 3, 2026Form 4Mokari AtabakChief Financial OfficerTax withholding · $3,453 · 96 sh
Mar 3, 2026Form 4Lyon Joseph DouglasSee RemarksTax withholding · $3,201 · 89 sh
Mar 2, 2026Form 4Robb Gary CharlesChief Business OfficerAward · $18K · 998 sh
Mar 2, 2026Form 4Guyer WilliamChief Development OfficerAward · $18K · 996 sh
Mar 2, 2026Form 4Maduck SeanSee RemarksAward · $16K · 908 sh
Mar 2, 2026Form 4Lyon Joseph DouglasSee RemarksAward · $14K · 796 sh
Mar 2, 2026Form 4Mokari AtabakChief Financial OfficerAward · $14K · 794 sh
Feb 27, 2026Form 4BELANOFF JOSEPH KChief Executive Officer · DirectorAward · Stock Option (right to buy) · $0 · 460,000 sh
Feb 27, 2026Form 4Guyer WilliamChief Development OfficerAward · Stock Option (right to buy) · $0 · 140,000 sh
Feb 27, 2026Form 4Robb Gary CharlesChief Business OfficerAward · Stock Option (right to buy) · $0 · 140,000 sh
Feb 27, 2026Form 4Hunt HazelChief Scientific OfficerAward · Stock Option (right to buy) · $0 · 140,000 sh
Feb 27, 2026Form 4Maduck SeanSee RemarksAward · Stock Option (right to buy) · $0 · 140,000 sh
Feb 27, 2026Form 4Mokari AtabakChief Financial OfficerAward · Stock Option (right to buy) · $0 · 140,000 sh
Feb 27, 2026Form 4Lyon Joseph DouglasSee RemarksAward · Stock Option (right to buy) · $0 · 140,000 sh
Feb 24, 2026Form 4WILSON JAMES NDirectorTax withholding · $388K · 10,636 sh
Feb 24, 2026Form 4WILSON JAMES NDirectorExercise or conversion · $388K · 100,000 sh
Feb 24, 2026Form 4WILSON JAMES NDirectorExercise or conversion · Stock option (right to buy) · $0 · 100,000 sh
Feb 24, 2026Form 4WILSON JAMES NDirectorGift · $0 · 89,364 sh
Feb 24, 2026Form 4WILSON JAMES NDirectorOther · $0 · 89,364 sh
Feb 9, 2026Form 4Hunt HazelChief Scientific OfficerTax withholding · $3.2M · 77,968 sh
Feb 9, 2026Form 4Hunt HazelChief Scientific OfficerExercise or conversion · $582K · 150,000 sh
Feb 9, 2026Form 4Hunt HazelChief Scientific OfficerExercise or conversion · Stock Option (right to buy) · $0 · 150,000 sh
Feb 3, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · $433K · 20,000 sh · 10b5-1
Feb 3, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · Stock option (right to buy) · $0 · 20,000 sh · 10b5-1
Jan 27, 2026Form 4BAKER G LEONARD JRDirectorExercise or conversion · $1.6M · 140,000 sh
Jan 27, 2026Form 4BAKER G LEONARD JRDirectorExercise or conversion · Stock Option (Right To Buy) · $0 · 140,000 sh
Jan 8, 2026Form 4Maduck SeanSee RemarksGift · $0 · 54,570 sh
Jan 8, 2026Form 4Maduck SeanSee RemarksOther · $0 · 54,570 sh
Jan 6, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · $433K · 20,000 sh · 10b5-1
Jan 6, 2026Form 4Guyer WilliamChief Development OfficerExercise or conversion · Stock option (right to buy) · $0 · 20,000 sh · 10b5-1
Jan 1, 2026Form 4BAKER G LEONARD JRDirectorGift · $0 · 0 sh

Reports and proxy statements#

Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K that furnishes a press release is headed by the release’s headline, its items beneath; any other 8-K is described by its items. A form opens the press release where there is one, else the document on EDGAR, or the filing’s index where it furnishes other exhibits.

2026 · 16 filings
FiledWhat it is
Nov 3, 202610-QQuarterly report, Q3 2026 — revenue $340.5M (+64% y/y), net income $126.8M, EPS $1.01
Nov 3, 20268-KEarnings release — EPS $1.01 vs $0.68 est. (+48.5%); revenue $340.5M (+64% y/y) 3.3%
Sep 23, 20268-KCorcept Announces Planned Leadership TransitionDirectors or officers; compensation; Regulation FD disclosure
Jul 29, 202610-QQuarterly report, Q2 2026 — revenue $256.1M (+32% y/y), net income $43.0M, EPS $0.36
Jul 29, 20268-KEarnings release — EPS $0.36 vs −$0.04 est. (+1000.0%); revenue $256.1M (+32% y/y) 27.3%
Jun 17, 20268-KCorcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s SyndromeOther events
Jun 3, 20268-KOther events
May 28, 20268-KDirectors or officers; compensation; Shareholder vote results
Apr 30, 202610-QQuarterly report, Q1 2026 — revenue $164.9M (+5% y/y), net income −$31.8M, EPS −$0.30
Apr 30, 20268-KEarnings release — EPS −$0.30 vs −$0.30 est. (+0.0%); revenue $164.9M (+5% y/y) 10.5%
Apr 17, 2026DEF 14AProxy statement
Mar 25, 20268-KOther events
Feb 24, 202610-KAnnual report, FY2025 — revenue $761.4M (+13% y/y), net income $99.7M, EPS $0.82
Feb 24, 20268-KEarnings release — EPS $0.20 vs $0.27 est. (−25.9%); revenue $202.1M (+11% y/y) 0.7%
Feb 19, 20268-KCorcept Provides Update on Patent Dispute with Teva PharmaceuticalsOther events
Jan 22, 20268-KOverall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian CancerOther events
2025 · 17 filings
FiledWhat it is
Dec 31, 20258-KCorcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with HypercortisolismOther events
Nov 4, 202510-QQuarterly report, Q3 2025 — revenue $207.6M (+14% y/y), net income $19.7M, EPS $0.16
Nov 4, 20258-KEarnings release — EPS $0.16 vs $0.18 est. (−11.1%); revenue $207.6M (+14% y/y) 7.8%
Oct 14, 20258-KTermination of a material agreement
Oct 6, 20258-KDirectors or officers; compensation
Sep 10, 20258-KOther events
Jul 31, 202510-QQuarterly report, Q2 2025 — revenue $194.4M (+19% y/y), net income $35.1M, EPS $0.29
Jul 31, 20258-KEarnings release — EPS $0.29 vs $0.23 est. (+26.1%); revenue $194.4M (+19% y/y) 2.7%
Jul 14, 20258-KOther events
Jun 16, 20258-KShareholder vote results
May 5, 202510-QQuarterly report, Q1 2025 — revenue $157.2M (+7% y/y), net income $20.5M, EPS $0.17
May 5, 20258-KEarnings release — EPS $0.17 vs $0.17 est.; revenue $157.2M (+7% y/y) 4.3%
Apr 25, 2025DEF 14AProxy statement
Mar 31, 20258-KOther events
Mar 3, 20258-KOther events
Feb 26, 202510-KAnnual report, FY2024 — revenue $675.0M (+40% y/y), net income $141.2M, EPS $1.23
Feb 26, 20258-KEarnings release — EPS $0.26 vs $0.37 est. (−29.7%); revenue $181.9M (+34% y/y) 5.6%
2024 · 16 filings
FiledWhat it is
Dec 30, 20248-KOther events
Oct 30, 202410-QQuarterly report, Q3 2024 — revenue $182.5M (+48% y/y), net income $47.2M, EPS $0.41
Oct 30, 20248-KEarnings release — EPS $0.41 vs $0.27 est. (+51.9%); revenue $182.5M (+48% y/y) 4.4%
Jul 29, 202410-QQuarterly report, Q2 2024 — revenue $163.8M (+39% y/y), net income $35.5M, EPS $0.32
Jul 29, 20248-KEarnings release — EPS $0.32 vs $0.23 est. (+39.1%); revenue $163.8M (+39% y/y) 1.1%
May 23, 20248-KDirectors or officers; compensation; Shareholder vote results
May 1, 202410-QQuarterly report, Q1 2024 — revenue $146.8M (+39% y/y), net income $27.8M, EPS $0.25
May 1, 20248-KEarnings release — EPS $0.25 vs $0.21 est. (+19.1%); revenue $146.8M (+39% y/y) 4.9%
Apr 18, 2024DEFA14AAdditional proxy materials
Apr 17, 2024ARSAnnual report to shareholders
Apr 17, 20248-KMaterial definitive agreement; New financial obligation
Apr 10, 2024DEF 14AProxy statement
Feb 15, 202410-KAnnual report, FY2023 — revenue $482.4M (+20% y/y), net income $106.1M, EPS $0.94
Feb 15, 20248-KEarnings release — EPS $0.28 vs $0.25 est. (+12.0%); revenue $135.4M (+31% y/y) 7.2%
Jan 8, 20248-KResults of operations; Other events
Jan 2, 20248-KOther events
2023 · 15 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 4 other forms
FiledWhat it is
Nov 1, 202310-QQuarterly report, Q3 2023 — revenue $123.6M (+22% y/y), net income $31.4M, EPS $0.28
Aug 2, 202310-QQuarterly report, Q2 2023 — revenue $117.7M (+14% y/y), net income $27.5M, EPS $0.25
May 8, 2023DEFA14AAdditional proxy materials
May 3, 202310-QQuarterly report, Q1 2023 — revenue $105.7M (+13% y/y), net income $15.9M, EPS $0.14
Apr 14, 2023ARSAnnual report to shareholders
Apr 14, 2023DEF 14AProxy statement
Apr 4, 2023PRE 14APreliminary proxy statement
Feb 28, 202310-KAnnual report, FY2022 — revenue $401.9M (+10% y/y), net income $101.4M, EPS $0.87

7 current reports (8-K) not listed; the year is on EDGAR.

2022 · 12 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
FiledWhat it is
Nov 3, 202210-QQuarterly report, Q3 2022 — revenue $101.7M (+6% y/y), net income $34.6M, EPS $0.30
Aug 4, 202210-QQuarterly report, Q2 2022 — revenue $103.4M (+13% y/y), net income $27.4M, EPS $0.24
May 5, 202210-QQuarterly report, Q1 2022 — revenue $93.7M (+18% y/y), net income $22.8M, EPS $0.20
Apr 25, 2022DEF 14AProxy statement
Feb 15, 202210-KAnnual report, FY2021 — revenue $366.0M (+3% y/y), net income $112.5M, EPS $0.89

7 current reports (8-K) not listed; the year is on EDGAR.

2021 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
FiledWhat it is
Nov 15, 202110-K/AAnnual report, amended
Nov 3, 202110-QQuarterly report, Q3 2021 — revenue $96.1M (+11% y/y), net income $30.5M, EPS $0.24
Jul 29, 202110-QQuarterly report, Q2 2021 — revenue $91.6M (+3% y/y), net income $26.5M, EPS $0.21
May 6, 202110-QQuarterly report, Q1 2021 — revenue $79.4M (−15% y/y), net income $23.5M, EPS $0.18
Apr 22, 2021DEF 14AProxy statement
Feb 23, 202110-KAnnual report, FY2020 — revenue $353.9M (+15% y/y), net income $106.0M, EPS $0.85

12 current reports (8-K) not listed; the year is on EDGAR.

2020 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
FiledWhat it is
Nov 3, 202010-QQuarterly report, Q3 2020 — revenue $86.3M (+6% y/y), net income $21.6M, EPS $0.17
Aug 4, 202010-QQuarterly report, Q2 2020 — revenue $88.6M (+23% y/y), net income $28.3M, EPS $0.23
May 4, 202010-QQuarterly report, Q1 2020 — revenue $93.2M (+44% y/y), net income $30.1M, EPS $0.25
Apr 27, 2020DEF 14AProxy statement
Feb 24, 202010-KAnnual report, FY2019 — revenue $306.5M (+22% y/y), net income $94.2M, EPS $0.77

10 current reports (8-K) not listed; the year is on EDGAR.

2019 · 14 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
FiledWhat it is
Nov 7, 201910-QQuarterly report, Q3 2019 — revenue $81.5M (+26% y/y), net income $26.3M, EPS $0.22
Aug 1, 201910-QQuarterly report, Q2 2019 — revenue $72.3M (+16% y/y), net income $20.2M, EPS $0.17
May 9, 201910-QQuarterly report, Q1 2019 — revenue $64.8M (+12% y/y), net income $18.3M, EPS $0.15
Apr 24, 2019DEF 14AProxy statement
Feb 26, 201910-KAnnual report, FY2018 — revenue $251.2M (+58% y/y), net income $75.4M, EPS $0.60

9 current reports (8-K) not listed; the year is on EDGAR.

2018 · 16 filings — 11 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
FiledWhat it is
Nov 2, 201810-QQuarterly report, Q3 2018 — revenue $64.4M (+51% y/y), net income $17.7M, EPS $0.14
Aug 9, 201810-QQuarterly report, Q2 2018 — revenue $62.3M (+75% y/y), net income $18.2M, EPS $0.14
May 9, 201810-QQuarterly report, Q1 2018 — revenue $57.7M (+109% y/y), net income $17.5M, EPS $0.14
Apr 24, 2018DEF 14AProxy statement
Feb 28, 201810-KAnnual report, FY2017 — revenue $159.2M (+96% y/y), net income $129.1M, EPS $1.04

11 current reports (8-K) not listed; the year is on EDGAR.

2017 · 14 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form
FiledWhat it is
Nov 3, 201710-QQuarterly report, Q3 2017 — revenue $42.8M, net income $13.8M, EPS $0.11
Aug 2, 201710-QQuarterly report, Q2 2017 — revenue $35.6M, net income $12.6M, EPS $0.10
May 2, 201710-QQuarterly report, Q1 2017 — revenue $27.6M, net income $4.4M, EPS $0.04
Apr 21, 2017DEF 14AProxy statement
Mar 6, 201710-KAnnual report, FY2016 — revenue $81.3M, net income $8.1M, EPS $0.07

9 current reports (8-K) not listed; the year is on EDGAR.

2016 · 12 filings — 7 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2015 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2014 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2013 · 18 filings — 12 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2012 · 18 filings — 13 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2011 · 24 filings — 19 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2010 · 24 filings — 18 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2009 · 15 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2008 · 14 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2007 · 24 filings — 16 × 8-K, 3 × 10-Q, 2 × DEF 14A and 3 other forms

Counted, not listed; the year is on EDGAR.

2006 · 15 filings — 9 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms

Counted, not listed; the year is on EDGAR.

2005 · 10 filings — 5 × 8-K, 3 × 10-Q, 1 × 10-K and 1 other form

Counted, not listed; the year is on EDGAR.

2004 · 10 filings — 7 × 8-K, 3 × 10-Q

Counted, not listed; the year is on EDGAR.

Insider, ownership and other filings#

Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.

2026 · 125 filings — 90 × 4, 27 × 144, 5 × SCHEDULE 13G/A and 2 other forms
FiledWhat it is
Nov 17, 20264Insider transaction (Form 4)
Nov 13, 20264Insider transaction (Form 4)
Nov 10, 2026144Notice of proposed sale (Form 144)
Nov 4, 20264Insider transaction (Form 4)
Nov 4, 20264Insider transaction (Form 4)
Oct 27, 2026SCHEDULE 13G/AOther filings
Oct 16, 20264Insider transaction (Form 4)
Oct 5, 20264Insider transaction (Form 4)
Oct 5, 20264Insider transaction (Form 4)
Oct 5, 20264Insider transaction (Form 4)
Oct 5, 20264Insider transaction (Form 4)
Oct 5, 20263Initial insider holdings (Form 3)
Oct 1, 2026144Notice of proposed sale (Form 144)
Sep 28, 20264Insider transaction (Form 4)
Sep 18, 20264Insider transaction (Form 4)
Sep 18, 20264Insider transaction (Form 4)
Sep 16, 20264Insider transaction (Form 4)
Sep 16, 20264Insider transaction (Form 4)
Sep 15, 2026144Notice of proposed sale (Form 144)
Sep 14, 2026144Notice of proposed sale (Form 144)
Sep 3, 20264Insider transaction (Form 4)
Sep 3, 20264Insider transaction (Form 4)
Sep 3, 20264Insider transaction (Form 4)
Sep 3, 20264Insider transaction (Form 4)
Sep 3, 20264Insider transaction (Form 4)

The newest 25 of 125 shown; the full year is on EDGAR.

2025 · 170 filings — 98 × 4, 63 × 144, 4 × SCHEDULE 13G/A and 4 other forms
FiledWhat it is
Dec 29, 20254Insider transaction (Form 4)
Dec 29, 20254Insider transaction (Form 4)
Dec 16, 20254Insider transaction (Form 4)
Dec 11, 2025UPLOADLetter from the SEC staff
Dec 3, 20254Insider transaction (Form 4)
Dec 3, 20254Insider transaction (Form 4)
Dec 3, 20254Insider transaction (Form 4)
Dec 3, 20254Insider transaction (Form 4)
Dec 3, 20254Insider transaction (Form 4)
Dec 3, 20254Insider transaction (Form 4)
Dec 3, 20254/AInsider transaction (Form 4), amended
Dec 2, 2025144Notice of proposed sale (Form 144)
Dec 1, 2025144Notice of proposed sale (Form 144)
Dec 1, 2025144Notice of proposed sale (Form 144)
Dec 1, 2025144Notice of proposed sale (Form 144)
Nov 26, 20254Insider transaction (Form 4)
Nov 25, 2025144Notice of proposed sale (Form 144)
Nov 7, 20254Insider transaction (Form 4)
Nov 5, 20254Insider transaction (Form 4)
Nov 5, 20254Insider transaction (Form 4)
Nov 5, 20254Insider transaction (Form 4)
Nov 5, 2025144Notice of proposed sale (Form 144)
Nov 3, 2025144Notice of proposed sale (Form 144)
Nov 3, 2025144Notice of proposed sale (Form 144)
Nov 3, 2025144Notice of proposed sale (Form 144)

The newest 25 of 170 shown; the full year is on EDGAR.

2024 · 126 filings — 75 × 4, 31 × 144, 11 × S-8 POS and 3 other forms
FiledWhat it is
Dec 31, 20244Insider transaction (Form 4)
Dec 12, 20244Insider transaction (Form 4)
Dec 10, 2024144Notice of proposed sale (Form 144)
Dec 4, 20244Insider transaction (Form 4)
Dec 4, 20244Insider transaction (Form 4)
Dec 4, 20244Insider transaction (Form 4)
Dec 4, 20244Insider transaction (Form 4)
Dec 4, 20244Insider transaction (Form 4)
Nov 26, 20244Insider transaction (Form 4)
Nov 26, 20244Insider transaction (Form 4)
Nov 22, 2024144Notice of proposed sale (Form 144)
Nov 22, 2024144Notice of proposed sale (Form 144)
Nov 13, 20244Insider transaction (Form 4)
Nov 12, 2024144Notice of proposed sale (Form 144)
Nov 5, 20244Insider transaction (Form 4)
Nov 1, 2024144Notice of proposed sale (Form 144)
Oct 3, 20244Insider transaction (Form 4)
Oct 1, 20244Insider transaction (Form 4)
Oct 1, 2024144Notice of proposed sale (Form 144)
Oct 1, 2024144Notice of proposed sale (Form 144)
Sep 19, 20244Insider transaction (Form 4)
Sep 5, 20244Insider transaction (Form 4)
Sep 5, 20244Insider transaction (Form 4)
Sep 5, 20244Insider transaction (Form 4)
Sep 5, 20244Insider transaction (Form 4)

The newest 25 of 126 shown; the full year is on EDGAR.

2023 · 111 filings — 69 × 4, 23 × 144, 6 × SC 13G/A and 7 other forms

Counted, not listed; the year is on EDGAR.

2022 · 51 filings — 40 × 4, 6 × SC 13G/A, 2 × 5 and 3 other forms

Counted, not listed; the year is on EDGAR.

2021 · 61 filings — 42 × 4, 4 × SC 13G/A, 4 × SC TO-I/A and 7 other forms

Counted, not listed; the year is on EDGAR.

2020 · 50 filings — 31 × 4, 7 × SC 13G/A, 4 × 3 and 6 other forms

Counted, not listed; the year is on EDGAR.

2019 · 30 filings — 19 × 4, 5 × SC 13G/A, 2 × 3 and 4 other forms

Counted, not listed; the year is on EDGAR.

2018 · 43 filings — 33 × 4, 4 × SC 13G/A, 2 × SC 13G and 4 other forms

Counted, not listed; the year is on EDGAR.

2017 · 45 filings — 22 × 4, 4 × 5, 3 × CORRESP and 10 other forms

Counted, not listed; the year is on EDGAR.

2016 · 34 filings — 27 × 4, 3 × SC 13G/A, 1 × 3 and 3 other forms

Counted, not listed; the year is on EDGAR.

2015 · 60 filings — 47 × 4, 3 × SC 13G/A, 2 × 3 and 6 other forms

Counted, not listed; the year is on EDGAR.

2014 · 25 filings — 16 × 4, 3 × SC 13G/A, 2 × CT ORDER and 4 other forms

Counted, not listed; the year is on EDGAR.

2013 · 28 filings — 15 × 4, 5 × 5, 3 × SC 13G/A and 3 other forms

Counted, not listed; the year is on EDGAR.

2012 · 62 filings — 36 × 4, 4 × CT ORDER, 3 × 3 and 12 other forms

Counted, not listed; the year is on EDGAR.

2011 · 66 filings — 49 × 4, 5 × SC 13G/A, 2 × 5 and 9 other forms

Counted, not listed; the year is on EDGAR.

2010 · 67 filings — 28 × 4, 6 × EFFECT, 5 × SC 13G/A and 13 other forms

Counted, not listed; the year is on EDGAR.

2009 · 95 filings — 56 × 4, 18 × 424B3, 4 × 4/A and 8 other forms

Counted, not listed; the year is on EDGAR.

2008 · 107 filings — 59 × 4, 6 × CORRESP, 5 × 3 and 14 other forms

Counted, not listed; the year is on EDGAR.

2007 · 106 filings — 69 × 4, 9 × SC 13G/A, 6 × 424B3 and 10 other forms

Counted, not listed; the year is on EDGAR.

2006 · 78 filings — 71 × 4, 3 × SC 13G/A, 2 × SC 13G and 2 other forms

Counted, not listed; the year is on EDGAR.

2005 · 80 filings — 70 × 4, 7 × SC 13G, 2 × 3 and 1 other form

Counted, not listed; the year is on EDGAR.

2004 · 53 filings — 24 × 4, 20 × 3, 3 × S-1/A and 6 other forms

Counted, not listed; the year is on EDGAR.

2003 · 1 filing — 1 × REGDEX/A

Counted, not listed; the year is on EDGAR.

2002 · 2 filings — 1 × RW, 1 × S-1/A

Counted, not listed; the year is on EDGAR.

2001 · 1 filing — 1 × S-1

Counted, not listed; the year is on EDGAR.

About this data#

Corcept Therapeutics Incorporated (CORT) has 2,045 filings on EDGAR going back to 2001: 24 annual reports, 70 quarterly reports and 244 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Nov 3, 2026, furnished a press release headed “Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update”. Over the last 13 months insiders sold $91.3M in 49 sales and bought $3.3M in 1 purchase; 144 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.

Every row is a filing EDGAR lists for the registrants that have been Corcept Therapeutics Incorporated, read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. An 8-K’s headline is the first line of the press release it furnishes (Exhibit 99), read from the filing and shown word for word; where two independent readings of the exhibit do not agree, the 8-K is described by its items instead. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.

FAQ#

Where can I read CORT's latest 10-K?
CORT's latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
When did CORT last file an 8-K?
On Nov 3, 2026 it furnished a press release headed “Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update”. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Nov 3, 2026.
Are CORT insiders buying or selling?
Over the last 13 months insiders sold $91.3M in 49 sales and bought $3.3M in 1 purchase; 144 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: WILSON JAMES N (Director) sold 10,000 shares on Nov 13, 2026 for $727K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
How many SEC filings has CORT made?
2,045 filings are on EDGAR under the registrant records that have been Corcept Therapeutics Incorporated, going back to 2001; 1,342 of them are insider ownership forms (Forms 3, 4, 5 and 144).